These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 1892433)

  • 1. [Pharmacokinetics of amphotericin B and its derivatives].
    Vetkina IF
    Antibiot Khimioter; 1991 Apr; 36(4):36-8. PubMed ID: 1892433
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical roundtable monograph: safety and efficacy of lipid-based amphotericin B.
    Bellmann R; Cleary JD; Sterba J
    Clin Adv Hematol Oncol; 2009 Apr; 7(4):1-8. PubMed ID: 19537331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Liposomal amphotericin B: a unique pharmacokinetic profile. An unfinished story].
    Azanza Perea JR; Barberán J
    Rev Esp Quimioter; 2012 Mar; 25(1):17-24. PubMed ID: 22488537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of tissue penetration on AmBisome efficacy.
    Adler-Moore J; Proffitt RT
    Curr Opin Investig Drugs; 2003 Feb; 4(2):179-85. PubMed ID: 12669379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in pharmacokinetics of amphotericin B lipid formulations despite clinical equivalence.
    Bellmann R; Egger P; Wiedermann CJ
    Clin Infect Dis; 2003 Jun; 36(11):1500-1. PubMed ID: 12766850
    [No Abstract]   [Full Text] [Related]  

  • 6. Antifungal agents--clinical pharmacokinetics and drug interactions.
    Lipp HP
    Mycoses; 2008; 51 Suppl 1():7-18. PubMed ID: 18471156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacokinetics and pharmacodynamics of antifungal drugs in children].
    Jullien V
    Arch Pediatr; 2011 May; 18 Suppl 1():S42-7. PubMed ID: 21596286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The solubility ceiling: a rationale for continuous infusion amphotericin B therapy?
    Lewis RE; Wiederhold NP
    Clin Infect Dis; 2003 Sep; 37(6):871-2. PubMed ID: 12955666
    [No Abstract]   [Full Text] [Related]  

  • 9. Lipid complexes of amphotericin B: the competitive picture.
    Richardson MD
    J Med Microbiol; 1997 Mar; 46(3):185-7. PubMed ID: 9126817
    [No Abstract]   [Full Text] [Related]  

  • 10. Enhanced amphotericin B nephrotoxicity in intensive care patients with elevated levels of low-density lipoprotein cholesterol.
    Wasan KM; Conklin JS
    Clin Infect Dis; 1997 Jan; 24(1):78-80. PubMed ID: 8994768
    [No Abstract]   [Full Text] [Related]  

  • 11. Drug therapy of systemic fungal infections, Part II.
    Gross M
    N C Med J; 1984 Sep; 45(9):551-3. PubMed ID: 6592453
    [No Abstract]   [Full Text] [Related]  

  • 12. The experience is CLEAR.
    Chandrasekar P
    Int J Antimicrob Agents; 2006 Jun; 27 Suppl 1():31-5. PubMed ID: 16707248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Choice and use of antifungal drugs].
    Dupont B
    Rev Prat; 2001 Apr; 51(7):752-7. PubMed ID: 11387672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of fungal infections with semisynthetic derivatives of amphotericin B alpha.
    Hoeprich PD; Flynn NM; Kawachi MM; Lee KK; Lawrence RM; Heath LK; Schaffner CP
    Ann N Y Acad Sci; 1988; 544():517-46. PubMed ID: 3214091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid formulations of amphotericin B.
    Dix SP; Andriole VT
    Curr Clin Top Infect Dis; 2000; 20():1-23. PubMed ID: 10943516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Commonly used antifungal agents in the treatment of systemic mycoses].
    Berenguer Berenguer J
    Rev Clin Esp; 1995 Oct; 195 Suppl 3():58-65. PubMed ID: 9441308
    [No Abstract]   [Full Text] [Related]  

  • 17. A benefit for renal function after early switch to liposomal amphotericin B from conventional formulation in empirical antifungal treatment.
    Isnard F; Tilleul P; Laporte JP; Chevallier P; Pigneux A; Lafuma A; Mahi L; Deray G
    Nephrol Dial Transplant; 2007 Oct; 22(10):3090-1. PubMed ID: 17595189
    [No Abstract]   [Full Text] [Related]  

  • 18. [Amphotericin B: the end of an era].
    Oude Lashof AM; Kullberg BJ
    Ned Tijdschr Geneeskd; 2004 Aug; 148(34):1665-8. PubMed ID: 15453116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of a polyene antifungal agent, liposomal amphotericin B (L-AMB), in a severely burned patient.
    Sasaki J; Matsumoto K; Fujishima S; Morita K; Hori S
    J Chemother; 2014 Oct; 26(5):312-4. PubMed ID: 24070023
    [No Abstract]   [Full Text] [Related]  

  • 20. Liposomal formulations of amphotericin B: differences according to the scientific evidence.
    Azanza JR; Sádada B; Reis J
    Rev Esp Quimioter; 2015 Dec; 28(6):275-81. PubMed ID: 26621170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.